Literature DB >> 31192150

Tyrosine Kinase Inhibitor Therapy in Locally Advanced Differentiated Thyroid Cancer: A Case Report.

Kirsten E Stewart1, Mark W J Strachan2, Devraj Srinivasan3, Morna MacNeill4, Lucy Wall3, Iain J Nixon1.   

Abstract

A 73-year-old female presenting with haemoptysis and dyspnoea was found to have a locally advanced left thyroid mass and vocal cord palsy. A CT scan of the neck and thorax and endoscopy demonstrated invasion into the tracheal lumen. Histopathology of the intraluminal tracheal mass confirmed a papillary thyroid cancer (PTC). The tumour was deemed unresectable due to local extent and patient comorbidities. TKI therapy with lenvatinib was used for 14 months. On serial scanning, a marked reduction in tumour volume from 31 × 59 × 32 mm to 17 × 28 × 22 mm was noted. This subsequently allowed a successful surgical resection with a total thyroidectomy and central neck dissection with no evidence of residual macroscopic disease. Histopathology confirmed a well-differentiated PTC with features of tumour regression. In this case, TKI therapy in a locally advanced unresectable DTC reduced tumour size and infiltration to a degree that surgical resection of macroscopic disease was possible, without requiring airway resection. This raises the possibility that TKIs may have a neoadjuvant role in selected cases of locally advanced DTC to reduce tumour volume and therefore morbidity of subsequent surgical resection.

Entities:  

Keywords:  Antineoplastic agents; Papillary carcinoma; Thyroid neoplasm; Treatment outcome; Tyrosine kinase inhibitors

Year:  2019        PMID: 31192150      PMCID: PMC6514483          DOI: 10.1159/000494880

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  14 in total

1.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

2.  Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement.

Authors:  Maisie L Shindo; Salvatore M Caruana; Emad Kandil; Judith C McCaffrey; Lisa A Orloff; John R Porterfield; Ashok Shaha; Jennifer Shin; David Terris; Gregory Randolph
Journal:  Head Neck       Date:  2014-08-23       Impact factor: 3.147

Review 3.  Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.

Authors:  Marcia S Brose
Journal:  Clin Adv Hematol Oncol       Date:  2016-05

4.  The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland.

Authors:  Iain J Nixon; Monica M Whitcher; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

5.  The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years.

Authors:  David T Hughes; Megan R Haymart; Barbra S Miller; Paul G Gauger; Gerard M Doherty
Journal:  Thyroid       Date:  2011-01-26       Impact factor: 6.568

6.  Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis.

Authors:  Luc G T Morris; David Myssiorek
Journal:  Am J Surg       Date:  2010-06-18       Impact factor: 2.565

7.  Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry.

Authors:  John D Cramer; Pingfu Fu; Karem C Harth; Seunghee Margevicius; Scott M Wilhelm
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

8.  [Prognosis of Papillary Thyroid Carcinoma with Local Invasion].

Authors:  Koichiro Yamada; Shinzo Tanaka; Yasuyuki Hiratsuka; Yohei Kumabe; Yoshiki Watanabe; Takao Yoshida; Masayoshi Yoshimatsu
Journal:  Nihon Jibiinkoka Gakkai Kaiho       Date:  2015-02

Review 9.  Lenvatinib: Role in thyroid cancer and other solid tumors.

Authors:  Maria E Cabanillas; Mouhammed Amir Habra
Journal:  Cancer Treat Rev       Date:  2015-12-02       Impact factor: 12.111

10.  Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma.

Authors:  Nikola Besic; Marija Auersperg; Marta Dremelj; Barbara Vidergar-Kralj; Barbara Gazic
Journal:  Thyroid       Date:  2013-02       Impact factor: 6.568

View more
  6 in total

1.  Rationale for therapeutic decision-making in locally advanced and metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, starting from a clinical case.

Authors:  Cristina Alina Silaghi; Oana Stãnoiu-Pînzariu; Horaţiu Silaghi; Doina Piciu; Carmen Emanuela Georgescu
Journal:  Arch Clin Cases       Date:  2021-12-29

Review 2.  Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer.

Authors:  Jing Li; Yingjie Zhang; Fenghao Sun; Ligang Xing; Xiaorong Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-08       Impact factor: 6.055

Review 3.  Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.

Authors:  Miguel-Ángel Berciano-Guerrero
Journal:  Cancer Med       Date:  2022-10       Impact factor: 4.711

Review 4.  Lenvatinib in multimodal therapy for unresectable radioactive iodine-naïve differentiated thyroid cancer: A case report with literature review.

Authors:  Hugh Andrew Jinwook Kim; Anthony Charles Nichols; Ramanamurthy Rachakonda; Richard Inculet; Jinka Sathya; Irina Rachinsky; Eric Winquist
Journal:  Cancer Rep (Hoboken)       Date:  2022-06-17

5.  Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: A case report.

Authors:  Yingchao Zhang; Xianzhao Deng; Zheng Ding; Jie Kang; Bo Wu; Bomin Guo; Youben Fan
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

Review 6.  Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review.

Authors:  Khalid Alshehri; Yousuf Alqurashi; Mazin Merdad; Shaza Samargandy; Razan Daghistani; Hani Marzouki
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.